Human immunodeficiency virus and liver disease: Conference proceedings

Hepatology

Volumn 51, Issue 3, 2010, Pages 1046-1054

  Sherman, Kenneth E ^a   Soriano, Vincent ^b   Chung, Raymond T ^c  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ADEFOVIR; ATAZANAVIR; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ENTECAVIR; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; INTEGRASE INHIBITOR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; PEGINTERFERON ALPHA; RALTEGRAVIR; RIBAVIRIN; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNINDEXED DRUG; ZIDOVUDINE;

CHRONIC DISEASE; CONFERENCE PAPER; DISEASE ASSOCIATION; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LIVER TRANSPLANTATION; OUTCOME ASSESSMENT; PATHOGENESIS; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; SOCIAL PSYCHOLOGY; TREATMENT RESPONSE; UNITED STATES; VIRUS TRANSMISSION;

HIV INFECTIONS; HUMANS; LIVER DISEASES;

EID: 77950624332     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23394     Document Type: Conference Paper

References (48)

1. Sherman KE, Peters M, Koziel MJ. HIV and liver disease forum: conference proceedings. HEPATOLOGY 2007;45:1566-1577.
2. Marks G, Millett GA, Bingham T, Bond L, Lauby J, Liau A, et al. Understanding differences in HIV sexual transmission among latino and black men who have sex with men: The Brothers y Hermanos Study. AIDS Behav 2009;13:682-690.
3. Sullivan PS, Hamouda O, Delpech V, Geduld JE, Prejean J, Semaille C, et al. Reemergence of the HIV epidemic among men who have sex with men in North America, Western Europe, and Australia, 1996-2005. Ann Epidemiol 2009;19:423-431.
4. Hall HI, Geduld J, Boulos D, Rhodes P, An Q, Mastro TD, et al. Epidemiology of HIV in the United States and Canada: current status and ongoing challenges. J Acquir Immune Defic Syndr 2009;51(Suppl. 1): S13-S20.
5. Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002;34:831-837.
6. Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006;44:S6-S9.
7. van de Laar T, Pybus O, Bruisten S, Brown D, Nelson M, Bhagani S, et al. Evidence of a large, international network of HCV transmission in HIV-positive men who have sex with men. Gastroenterology 2009;136:1609-1617.
8. Danta M, Dusheiko GM. Acute HCV in HIV-positive individuals-a review. Curr Pharm Des 2008;14:1690-1697.
9. Fierer DS, Uriel AJ, Carriero DC, Klepper A, Dieterich DT, Mullen MP, et al. Liver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study. J Infect Dis 2008;198: 683-686.
10. Benhamou Y, Bochet M, Di Martino V, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. HEPATOLOGY 1999;30:1054-1058. (Pubitemid 29458296)
11. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
12. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007;21:2209-2216.
13. Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006;166:1632-1641.
14. Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006;44:47-55.
15. Montes ML, Pascual J, Lopez-Dieguez M, Tural C, Quereda C, Ortega E, etal.; and GESIDA. Survival of HIV/HCV co-infected patients with compensated liver cirrhosis: effects of HCV therapy [Abstract]. Presented at: 16th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2009; Montreal, Canada. Abstract 106.
16. Mocroft A, Phillips AN, Soriano V, Rockstroh J, Blaxhult A, Katlama C, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005;21:743-752. (Pubitemid 41434178)
17. Sterling RK, Chiu S, Snider K, Nixon D. The prevalence and risk factors for abnormal liver enzymes in HIV-positive patients without hepatitis B or C coinfections. Dig Dis Sci 2008;53:1375-1382.
18. Graham CS, Curry M, He Q, Afdhal N, Nunes D, Fleming C, et al. Comparison of HCV-specific intrahepatic CD4+ T cells in HIV/HCV versus HCV. HEPATOLOGY 2004;40:125-132.
19. Lin W, Weinberg EM, Tai AW, Peng LF, Brockman MA, Kim KA, et al. HIV increases HCV replication in a TGF-beta1-dependent manner. Gastroenterology 2008;134:803-811.
20. TuyamaA, Hong F, Schecter A, Mosoian A, Chen B, Chen P, et al. HIV entry and replication in stellate cells promotes cellular activation and fibro-genesis: implications for hepatic fibrosis in HIV/HCV co-infection [Abstract]. In: 58th Annnual Meeting of the American Association for the Study of Liver Diseases; November 2-6, 2007; Boston, MA. Abstract LB3.
21. Balasubramanian A, Koziel M, Groopman JE, Ganju RK. Molecular mechanism of hepatic injury in coinfection with hepatitis C virus and HIV. Clin Infect Dis 2005;41(Suppl. 1):S32-S37.
22. BrenchleyJM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12:1365-1371.
23. Barve SS, Kelkar SV, Gobejishvilli L, Joshi-Barve S, McClain CJ. Mechanisms of alcohol-mediated CD4+ T lymphocyte death: relevance to HIV and HCV pathogenesis. Front Biosci 2002;7:d1689-d1696.
24. Dong Q, Kelkar S, Xiao Y, Joshi-Barve S, McClain CJ, Barve SS. Ethanol enhances TNF-alpha-inducible NFkappaB activation and HIV-1-LTR transcription in CD4+ Jurkat T lymphocytes. J Lab Clin Med 2000;136: 333-343.
25. Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis 2005;192:1943-1949.
26. Halfon P, Penaranda G, Carrat F, Bedossa P, Bourliere M, Ouzan D, et al. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients. Aliment Pharmacol Ther 2009;30:61-70.
27. BlackardJT, Sherman KE. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? J Viral Hepat 2008;15:323-330.
28. Schiano TD, Kotler DP, Ferran E, Fiel MI. Hepatoportal sclerosis as a cause of noncirrhotic portal hypertension in patients with HIV. Am J Gastroenterol 2007;102:2536-2540.
29. Dinh MH, Stosor V, Rao SM, Miller FH, Green RM. Cryptogenic liver disease in HIV-seropositive men. HIV Med 2009;10:447-453.
30. Ho DD. Time to hit HIV, early and hard. N Engl J Med 1995;333:450-451.
31. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, et al. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel. JAMA 2008;300: 555-570.
32. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009;360:1815-1826.
33. Clumeck N, Pozniak A, Raffi F. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. HIV Med 2008;9:65-71.
34. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008;47:266-285.
35. Blackard J, Hiasa Y, Smeaton L, Jamieson D, Rodriguez I, Mayer K, et al. Compartmentalization of hepatitis C virus (HCV) during HCV/HIV coinfection. J Infect Dis 2007;195:1765-1773.
36. Blackard JT, Kemmer N, Sherman KE. Extrahepatic replication of HCV: insights into clinical manifestations and biological consequences. HEPA-TOLOGY 2006;44:15-22.
37. Sherman KE, Andersen J, Butt A, Goodman Z, Umbleja T, Alston B, et al; and ACTG A5178 Study Team. Sustained long-term antiviral maintenance with pegylated interferon in HCV/HIV coinfected patients: early viral response and effect on fibrosis in treated and control subjects [Abstract]. Presented at: 15th Conference on Retroviruses and Opportunistic Infections; February 3-6, 2008; Boston, MA. Abstract 59.
38. Nunez M, Miralles C, Berdun MA, Losada E, Aguirrebengoa K, Ocampo A, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-982.
39. Shire NJ, Welge JA, Sherman KE. Response rates to pegylated interferon and ribavirin in HCV/HIV coinfection: a research synthesis. J Viral Hepat 2007;14:239-248.
40. Sherman KE, Fleischer R, Laessig K, Murray J, Tauber W, Birnkrant D. Development of novel agents for the treatment of chronic hepatitis C infection: Summary of the FDA Antiviral Products Advisory Committee recommendations. HEPATOLOGY 2007;46:2014-2020.
41. Butt AA, Khan UA, Shaikh OS, McMahon D, Dorey-Stein Z, Tsevat J, et al. Rates of HCV treatment eligibility among HCV-monoinfected and HCV/HIV-coinfected patients in tertiary care referral centers. HIV Clin Trials 2009;10:25-32.
42. Butt AA, Justice AC, Skanderson M, Rigsby MO, Good CB, Kwoh CK. Rate and predictors of treatment prescription for hepatitis C. Gut 2007; 56:385-389.
43. Maida I, Soriano V, Ramos B, Rios P, Gonzalez-Lahoz J, Nunez M. Characteristics and prospects for hepatitis C therapy of an HIV-HCV coin-fected population followed at a reference HIV center. HIV Clin Trials 2005;6:329-336.
44. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, Munoz A, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multi-center Cohort Study (MACS). Lancet 2002;360:1921-1926.
45. Soriano V, Vispo E, Bottecchia M, Sheldon J, Tuma P, Garcia-Samaniego J, et al. Management of hepatitis B virus co-infection on and off antiretro-viral therapy. Curr HIV/AIDS Rep 2008;5:86-93. (Pubitemid 351656422)
46. McMahon MA, Jilek BL, Brennan TP, Shen L, Zhou Y, Wind-Rotolo M, et al. The HBV drug entecavir-effects on HIV-1 replication and resistance. N Engl J Med 2007;356:2614-2621.
47. Maida I, Garcia-Gasco P, Sotgiu G, Rios MJ, Vispo ME, Martin-Carbon-ero L, et al. Antiretroviral-associated portal hypertension: a new clinical condition? Prevalence, predictors and outcome. Antivir Ther 2008;13: 103-107.
48. Stock PG. Rapid deterioration ofHIV co-infected patients waiting for liver transplantation is not predicted by MELD. Liver Transpl 2005;11:1315-1317.